Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

22 août 2025 08h00 HE | Source: BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics Announces First Patient Dosed in Expansion Cohorts of the Phase 1/2 SOLARA Trial, Evaluating BH-30643 in Advanced EGFR-mutant Non-Small Cell Lung Cancer

BlossomHill Therapeutics, Inc. today announced the first patient dosed in the expansion cohorts of the SOLARA trial, the first-in-human trial of BH-30643.
09 mai 2025 08h00 HE | Source: BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice President

SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines...
03 mars 2021 16h01 HE | Source: BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics Closes $71M Series A Financing

SAN DIEGO, March 03, 2021 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a biopharmaceutical company focusing on oncology and autoimmune disorders, announced today that the company raised $71...